{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:16:18Z","timestamp":1783448178538,"version":"3.55.0"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015042","name":"R\u012bgas Stradi\u0146a Universit\u0101te","doi-asserted-by":"publisher","award":["RSU-ZG-2024\/1-0036"],"award-info":[{"award-number":["RSU-ZG-2024\/1-0036"]}],"id":[{"id":"10.13039\/501100015042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["#2023-00356, #2022-01018, #2019-02397"],"award-info":[{"award-number":["#2023-00356, #2022-01018, #2019-02397"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018707","name":"HORIZON EUROPE Reforming and enhancing the European Research and Innovation system","doi-asserted-by":"publisher","award":["No 101053962"],"award-info":[{"award-number":["No 101053962"]}],"id":[{"id":"10.13039\/100018707","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer\u2019s Drug Discovery Foundation","doi-asserted-by":"publisher","award":["#201809-2016862"],"award-info":[{"award-number":["#201809-2016862"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer\u2019s Association","doi-asserted-by":"publisher","award":["(#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C"],"award-info":[{"award-number":["(#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019599","name":"European Partnership on Metrology","doi-asserted-by":"publisher","award":["#22HLT07"],"award-info":[{"award-number":["#22HLT07"]}],"id":[{"id":"10.13039\/100019599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007625","name":"Cure Alzheimer\u2019s Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021720","name":"Olav Thon Stiftelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021720","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007436","name":"Familjen Erling-Perssons Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010815","name":"Stiftelsen f\u00f6r Gamla Tj\u00e4narinnor","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010815","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","award":["(#FO2022-0270"],"award-info":[{"award-number":["(#FO2022-0270"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018694","name":"HORIZON EUROPE Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012621","name":"University College London Hospitals Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017510","name":"UK Dementia Research Institute","doi-asserted-by":"publisher","award":["UKDRI-1003"],"award-info":[{"award-number":["UKDRI-1003"]}],"id":[{"id":"10.13039\/501100017510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2017-00915 and #2022-00732"],"award-info":[{"award-number":["2017-00915 and #2022-00732"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["(#AF-930351, #AF-939721, #AF-968270, and #AF-994551"],"award-info":[{"award-number":["(#AF-930351, #AF-939721, #AF-968270, and #AF-994551"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","award":["ALZ2022-0006, #FO2024-0048-TK-130 and FO2024-0048-HK-24"],"award-info":[{"award-number":["ALZ2022-0006, #FO2024-0048-TK-130 and FO2024-0048-HK-24"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer\u2019s Association","doi-asserted-by":"publisher","award":["ZEN-21-848495, SG-23-1038904 QC"],"award-info":[{"award-number":["ZEN-21-848495, SG-23-1038904 QC"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007505","name":"Kirsten og Freddy Johansens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007436","name":"Familjen Erling-Perssons Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To evaluate plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) as candidate biomarkers in myasthenia gravis (MG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Ninety MG patients and 40 healthy controls were recruited. Disease severity was assessed by the Myasthenia Gravis Foundation of America (MGFA) classification, Myasthenia Gravis Composite (MGC) score, and Myasthenia Gravis Activities of Daily Living (MG-ADL) scale. Plasma NfL and GFAP were quantified using Single Molecule Array (Simoa) assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      NfL and GFAP plasma concentration did not differ between MG and controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). Neither biomarker correlated with MG-ADL or MGC, and no differences were observed across MGFA classes (p\u2009&gt;\u20090.05). Biomarker levels were unrelated to myasthenic crisis history or treatment exposure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Plasma NfL and GFAP, although informative in other neuroimmunological and neurodegenerative conditions, do not distinguish MG from healthy controls and show no association with disease severity. This study adds to the emerging literature on NfL in MG and represents one of the larger controlled analyses incorporating both NfL and GFAP biomarkers in this disease. The findings argue against adopting NfL or GFAP for MG monitoring and highlight the need for MG-specific biomarker strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0352017","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:34:04Z","timestamp":1783445644000},"page":"e0352017","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of plasma neurofilament light chain and glial fibrillary acidic protein in myasthenia gravis: A controlled cohort study"],"prefix":"10.1371","volume":"21","author":[{"given":"Arta","family":"Grosmane-Bataraga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evita","family":"Saluv\u0113ra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Roddate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3596-9661","authenticated-orcid":true,"given":"Vladimirs","family":"Krutovs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maksims","family":"Zolovs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nata\u013cja","family":"Kurj\u0101ne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7468-1908","authenticated-orcid":true,"given":"Viktorija","family":"\u0136\u0113ni\u0146a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"issue":"11","key":"pone.0352017.ref001","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"L Dresser","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"pone.0352017.ref002","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/ene.15565","article-title":"Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: a systematic review and expert appraisal","volume":"30","author":"A Meisel","year":"2023","journal-title":"Eur J Neurol"},{"key":"pone.0352017.ref003","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fimmu.2020.00213","article-title":"Circulating miRNAs as potential biomarkers in myasthenia gravis: tools for personalized medicine","volume":"11","author":"L Sabre","year":"2020","journal-title":"Front Immunol"},{"key":"pone.0352017.ref004","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3390\/cells11040740","article-title":"miR-30e-5p, miR-150-5p and miR-21-5p","volume":"11","author":"F Beretta","year":"2022","journal-title":"Cells"},{"issue":"8","key":"pone.0352017.ref005","doi-asserted-by":"crossref","first-page":"110564","DOI":"10.1016\/j.isci.2024.110564","article-title":"Serum protein biomarker profile distinguishes acetylcholine receptor antibody seropositive myasthenia gravis patients from healthy controls","volume":"27","author":"AK Bhandage","year":"2024","journal-title":"iScience"},{"key":"pone.0352017.ref006","doi-asserted-by":"crossref","first-page":"642384","DOI":"10.3389\/fnins.2021.642384","article-title":"The evolution of neurofilament light chain in multiple sclerosis","volume":"15","author":"C Ferreira-Atuesta","year":"2021","journal-title":"Front Neurosci"},{"issue":"4","key":"pone.0352017.ref007","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcac174","article-title":"Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5-90 years","volume":"4","author":"J Simr\u00e9n","year":"2022","journal-title":"Brain Commun"},{"issue":"8","key":"pone.0352017.ref008","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"L Gaetani","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"pone.0352017.ref009","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/ene.15858","article-title":"Plasma neurofilament light chain level is not a biomarker of Charcot-Marie-Tooth disease progression: results of 3-year follow-up study","volume":"30","author":"S Setlere","year":"2023","journal-title":"Eur J Neurol"},{"key":"pone.0352017.ref010","doi-asserted-by":"crossref","first-page":"1056322","DOI":"10.3389\/fneur.2022.1056322","article-title":"Serum neurofilament light chain in myasthenia gravis subgroups: an exploratory cohort and case-control study","volume":"13","author":"F Stascheit","year":"2023","journal-title":"Front Neurol"},{"issue":"12","key":"pone.0352017.ref011","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00415-025-13498-y","article-title":"Plasma NfL and GFAP in the preclinical stages of neurodegenerative diseases: insights from the UK Biobank","volume":"272","author":"J Buonocore","year":"2025","journal-title":"J Neurol"},{"issue":"6","key":"pone.0352017.ref012","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213400","article-title":"Comparative performances of 4 serum NfL assays, pTau181, and GFAP in patients with amyotrophic lateral sclerosis","volume":"104","author":"E Mondesert","year":"2025","journal-title":"Neurology"},{"key":"pone.0352017.ref013","doi-asserted-by":"crossref","first-page":"824888","DOI":"10.3389\/fnins.2022.824888","article-title":"Microglia and astrocyte function and communication: what do we know in humans?","volume":"16","author":"EF Garland","year":"2022","journal-title":"Front Neurosci"},{"issue":"1","key":"pone.0352017.ref014","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/cells14010047","article-title":"Schwann cells in neuromuscular disorders: a spotlight on amyotrophic lateral sclerosis","volume":"14","author":"KR Moss","year":"2025","journal-title":"Cells"},{"issue":"21","key":"pone.0352017.ref015","doi-asserted-by":"crossref","first-page":"15559","DOI":"10.3390\/ijms242115559","article-title":"Characterisation of GFAP-expressing glial cells in the dorsal root ganglion after spared nerve injury","volume":"24","author":"EA Konnova","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"11","key":"pone.0352017.ref016","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.1007\/s00415-023-11908-7","article-title":"Peripheral nervous system involvement accompanies central nervous system involvement in anti-glial fibrillary acidic protein (GFAP) antibody-related disease","volume":"270","author":"J Theuriet","year":"2023","journal-title":"J Neurol"},{"issue":"1","key":"pone.0352017.ref017","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards","volume":"55","author":"A Jaretzki","year":"2000","journal-title":"Neurology"},{"issue":"18","key":"pone.0352017.ref018","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG composite","volume":"74","author":"TM Burns","year":"2010","journal-title":"Neurology"},{"issue":"5","key":"pone.0352017.ref019","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/mus.22140","article-title":"MG composite and MG-QOL15 study group. MG-ADL: still a relevant outcome measure","volume":"44","author":"S Muppidi","year":"2011","journal-title":"Muscle Nerve"},{"issue":"16","key":"pone.0352017.ref020","doi-asserted-by":"crossref","first-page":"12751","DOI":"10.3390\/ijms241612751","article-title":"Circulating neurofilament light chain levels increase with age and are associated with worse physical function and body composition in men but not in women","volume":"24","author":"X Capo","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"pone.0352017.ref021","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3233\/JND-210693","article-title":"Habitual physical activity in patients with myasthenia gravis assessed by accelerometry and questionnaire","volume":"9","author":"LK Andersen","year":"2022","journal-title":"J Neuromuscul Dis"},{"issue":"5","key":"pone.0352017.ref022","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s00415-010-5823-x","article-title":"Comparison of muscle ultrastructure in myasthenia gravis with anti-MuSK and anti-AChR antibodies","volume":"258","author":"G Cenacchi","year":"2011","journal-title":"J Neurol"},{"issue":"1","key":"pone.0352017.ref023","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2990.2008.00965.x","article-title":"Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR","volume":"35","author":"S Martignago","year":"2009","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"5","key":"pone.0352017.ref024","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.nmd.2019.03.009","article-title":"A review of the histopathological findings in myasthenia gravis: Clues to the pathogenesis of treatment-resistance in extraocular muscles","volume":"29","author":"TA Europa","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"pone.0352017.ref025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/mus.27838","article-title":"Remodeling of the neuromuscular junction in myasthenia gravis increases serum neurofilament heavy chain levels","volume":"68","author":"SH Wong","year":"2023","journal-title":"Muscle Nerve"},{"issue":"6","key":"pone.0352017.ref026","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","article-title":"Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker","volume":"38","author":"Z Yang","year":"2015","journal-title":"Trends Neurosci"},{"issue":"2","key":"pone.0352017.ref027","doi-asserted-by":"crossref","first-page":"494","DOI":"10.14336\/AD.2020.0708","article-title":"Terminal Schwann cell aging: implications for age-associated neuromuscular dysfunction","volume":"12","author":"S Fuertes-Alvarez","year":"2021","journal-title":"Aging Dis"},{"issue":"1","key":"pone.0352017.ref028","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41398-020-01137-1","article-title":"Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer\u2019s disease","volume":"11","author":"P Chatterjee","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"8","key":"pone.0352017.ref029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135886","article-title":"Levels and age dependency of neurofilament light and glial fibrillary acidic protein in healthy individuals and their relation to the brain parenchymal fraction","volume":"10","author":"M V\u00e5gberg","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"pone.0352017.ref030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40478-020-00907-8","article-title":"Meta-analysis of human prefrontal cortex reveals activation of GFAP and decline of synaptic transmission in the aging brain","volume":"8","author":"W Wruck","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"pone.0352017.ref031","doi-asserted-by":"crossref","first-page":"100550","DOI":"10.1016\/j.ensci.2025.100550","article-title":"The role of Neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in MS and AQP4-NMOSD: advancing clinical applications","volume":"38","author":"S Samadzadeh","year":"2025","journal-title":"eNeurologicalSci"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0352017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:34:14Z","timestamp":1783445654000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0352017"}},"subtitle":[],"editor":[{"given":"Karlo","family":"Toljan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0352017","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]}}}